{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:32:08Z","timestamp":1794918728172,"version":"4.9.1"},"reference-count":48,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ama221604"],"award-info":[{"award-number":["JP25ama221604"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24KJ1535"],"award-info":[{"award-number":["JP24KJ1535"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Radiolabeled heterodimers targeting prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) have been extensively investigated to overcome heterogeneous target expression in prostate cancer. However, low tumor retention and high kidney uptake remain major challenges. In this study, we designed and synthesized a novel albumin binder (ALB)-modified PSMA\/GRPR-targeting heterodimer, PADA, to improve tumor retention and tumor-to-kidney ratios. [111In]In-PADA exhibited marked binding ability to albumin, PSMA, and GRPR in vitro. In biodistribution studies, the tumor retention of [111In]In-PADA was improved by the introduction of ALB in both PSMA-positive and GRPR-positive tumor-bearing mice. Overall, the tumor AUC values and tumor-to-kidney AUC value ratios of [111In]In-PADA were higher than those of a control agent without an ALB moiety in both model mice. In single-photon emission computed tomography (SPECT) imaging studies, [111In]In-PADA could be used to successfully visualize both PSMA-positive and GRPR-positive tumors and exhibited enhanced tumor-to-kidney contrast due to the introduction of ALB. These results suggest that [111In]In-PADA exhibits favorable pharmacokinetics as a PSMA\/GRPR-targeting heterodimer.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00209","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:50:33Z","timestamp":1784051433000},"page":"4166-4180","source":"Crossref","is-referenced-by-count":1,"title":["Improving Pharmacokinetics of PSMA\/GRPR-Targeting\nRadiolabeled Heterodimer through Enhanced Albumin Binding"],"prefix":"10.1021","volume":"23","author":[{"given":"Shohei","family":"Tsuchihashi","sequence":"first","affiliation":[{"name":"Kyoto University , , 46-29 Yoshida Shimoadachi-cho , Sakyo-Ku, ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3462-7354","authenticated-orcid":true,"given":"Kazuma","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Kyoto University , , 46-29 Yoshida Shimoadachi-cho , Sakyo-Ku, ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-1224","authenticated-orcid":true,"given":"Hiroyuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Kyoto University , , 46-29 Yoshida Shimoadachi-cho , Sakyo-Ku, ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2497-039X","authenticated-orcid":true,"given":"Masahiro","family":"Ono","sequence":"additional","affiliation":[{"name":"Kyoto University , , 46-29 Yoshida Shimoadachi-cho , Sakyo-Ku, ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"7","key":"2026080309073890600_cit1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","article-title":"Metastatic Castration-resistant\nProstate Cancer: Advances\nin Treatment and Symptom Management","volume":"25","author":"Kulasegaran","year":"2024","journal-title":"Curr. Treat.\nOptions Oncol."},{"issue":"3","key":"2026080309073890600_cit2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics\n2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for\n36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"2026080309073890600_cit3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.semradonc.2025.05.004","article-title":"PSMA-PET Guided Radiotherapy in Prostate\nCancer: A Critical Review of Current Applications and Future Directions","volume":"35","author":"Dragonetti","year":"2025","journal-title":"Semin. Radiat. Oncol."},{"key":"2026080309073890600_cit4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117829","article-title":"PSMA Targeted Therapy: From Molecular\nMechanisms to Clinical Breakthroughs in Castration-resistant Prostate\nCancer","volume":"296","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"2026080309073890600_cit5","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-03061-0","article-title":"Theranostics\nin Nuclear Medicine: the Era of Precision Oncology","volume":"42","author":"Gandhi","year":"2025","journal-title":"Med. Oncol."},{"issue":"7","key":"2026080309073890600_cit6","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic\nLandscape: A Review\nof Clinical and Preclinical Development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur.\nJ. Nucl. Med. Mol. Imaging"},{"key":"2026080309073890600_cit7","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1007\/s00259-025-07661-w","article-title":"Efficacy,\nToxicity, and Clinical Outcomes of 177Lu-PSMA-617 Radioligand\nTherapy at 5.5 GBq Per Cycle in Patients\nwith Advanced Castration-resistant Prostate Cancer: a Prospective,\nSingle Arm, Phase II Study","volume":"53","author":"Marini","year":"2026","journal-title":"Eur. J. Nucl. Med.\nMol. Imaging"},{"key":"2026080309073890600_cit8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12149-025-02127-3","article-title":"Efficacy and Safety of Lutetium-177\n(177Lu)-PSMA-617 in Metastatic Castration-resistant Prostate\nCancer Patients with Superscan Pattern: A Retrospective Cohort Study","volume":"40","author":"Shamshirgaran","year":"2026","journal-title":"Ann. Nucl. Med."},{"issue":"10","key":"2026080309073890600_cit9","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2967\/jnumed.121.263441","article-title":"Outcome of\nPatients\nwith PSMA PET\/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis","volume":"63","author":"Hotta","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026080309073890600_cit10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","article-title":"Poor Outcomes\nfor Patients with Metastatic\nCastration-resistant Prostate Cancer with Low Prostate-Specific Membrane\nAntigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled\nPSMA Radioligand Therapy","volume":"2","author":"Thang","year":"2019","journal-title":"Eur. Urol. Oncol."},{"issue":"4","key":"2026080309073890600_cit11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in Metastatic\nCastration-resistant Prostate Cancer: Correlations Between Pretherapeutic\nImaging and Whole-Body Tumor Dosimetry with Treatment Outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"5","key":"2026080309073890600_cit12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/pros.24104","article-title":"Imaging\nExpression of\nProstate-Specific Membrane Antigen and Response to PSMA-targeted Beta-emitting\nRadionuclide Therapies in Metastatic Castration-resistant Prostate\nCancer","volume":"81","author":"Vlachostergios","year":"2021","journal-title":"Prostate"},{"issue":"9","key":"2026080309073890600_cit13","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1021\/acs.molpharmaceut.4c00066","article-title":"Radiopharmaceuticals\nTargeting Gastrin-Releasing Peptide Receptor\nfor Diagnosis and Therapy of Prostate Cancer","volume":"21","author":"Zou","year":"2024","journal-title":"Mol. Pharm."},{"issue":"3","key":"2026080309073890600_cit14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.122.263889","article-title":"Comparison of 68Ga-PSMA-617\nPET\/CT and 68Ga-RM2 PET\/CT in Patients\nwith Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy:\nA Prospective, Single-Arm, Single-Center, Phase II Study","volume":"64","author":"Schollhammer","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"11","key":"2026080309073890600_cit15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","article-title":"PSMA- and GRPR-Targeted PET: Results from 50 Patients\nwith Biochemically Recurrent Prostate Cancer","volume":"62","author":"Baratto","year":"2021","journal-title":"J. Nucl. Med."},{"key":"2026080309073890600_cit16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1199432","article-title":"GRPR Versus PSMA:\nExpression Profiles During Prostate Cancer Progression Demonstrate\nthe Added Value of GRPR-targeting Theranostic Approaches","volume":"13","author":"Verhoeven","year":"2023","journal-title":"Front. Oncol."},{"issue":"2","key":"2026080309073890600_cit17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ird3.62","article-title":"Elevating\nTheranostics:\nThe Emergence and Promise of Radiopharmaceutical Cell-targeting Heterodimers\nin Human Cancers","volume":"2","author":"Chambers","year":"2024","journal-title":"iRadiology"},{"issue":"11","key":"2026080309073890600_cit18","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500128","article-title":"Two Targets,\nOne Mission: Heterobivalent Metal-Based Radiopharmaceuticals for Prostate\nCancer Imaging and Therapy","volume":"20","author":"Sobral","year":"2025","journal-title":"ChemMedChem"},{"issue":"4","key":"2026080309073890600_cit19","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1021\/acs.jmedchem.0c01785","article-title":"Development of Heterobivalent\nTheranostic Probes Having High Affinity\/Selectivity for the GRPR\/PSMA","volume":"64","author":"Bandari","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026080309073890600_cit20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.nucmedbio.2014.01.001","article-title":"Synthesis\nand Biological Evaluation of Copper-64 Radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7\u201314)NH2],\na Novel Bivalent Targeting Vector Having Affinity for Two Distinct\nBiomarkers (GRPr\/PSMA) of Prostate Cancer","volume":"41","author":"Bandari","year":"2014","journal-title":"Nucl.\nMed. Biol."},{"issue":"11","key":"2026080309073890600_cit21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16111358","article-title":"Theranostic\nPotential of the iPSMA-Bombesin\nRadioligand in Patients with Metastatic Prostate Cancer: A Pilot Study","volume":"16","author":"Gonza\u0301lez-Rueda","year":"2024","journal-title":"Pharmaceutics"},{"issue":"11","key":"2026080309073890600_cit22","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1021\/acsmedchemlett.4c00324","article-title":"Synthesis and Preclinical Evaluation\nof a Bispecific\nPSMA-617\/RM2 Heterodimer Targeting Prostate Cancer","volume":"15","author":"Liolios","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"2026080309073890600_cit23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jlcr.3749","article-title":"Bispecific Radioligands\nTargeting Prostate-Specific Membrane Antigen and Gastrin-Releasing\nPeptide Receptors on the Surface of Prostate Cancer Cells","volume":"62","author":"Liolios","year":"2019","journal-title":"J. Labelled Comp. Radiopharm."},{"issue":"3","key":"2026080309073890600_cit24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1021\/acs.bioconjchem.5b00687","article-title":"Novel Bispecific\nPSMA\/GRPr Targeting Radioligands with Optimized Pharmacokinetics for\nImproved PET Imaging of Prostate Cancer","volume":"27","author":"Liolios","year":"2016","journal-title":"Bioconjugate\nChem."},{"issue":"7","key":"2026080309073890600_cit25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12070614","article-title":"Heterodimeric Radiotracer\nTargeting PSMA and GRPR for\nImaging of Prostate Cancer-Optimization of the Affinity towards PSMA\nby Linker Modification in Murine Model","volume":"12","author":"Lundmark","year":"2020","journal-title":"Pharmaceutics"},{"issue":"3","key":"2026080309073890600_cit26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1021\/acs.bioconjchem.8b00919","article-title":"Bench to Bedside: Albumin\nBinders for Improved Cancer Radioligand\nTherapies","volume":"30","author":"Lau","year":"2019","journal-title":"Bioconjugate Chem."},{"issue":"9","key":"2026080309073890600_cit27","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1021\/acs.molpharmaceut.5c00693","article-title":"Albumin\nBinding as a Strategy for Improving Tumor Targeting\nof Radiolabeled Compounds","volume":"22","author":"Rahmati","year":"2025","journal-title":"Mol. Pharm."},{"issue":"12","key":"2026080309073890600_cit28","doi-asserted-by":"publisher","first-page":"8043","DOI":"10.1021\/acs.jmedchem.3c00346","article-title":"Development of Novel 111In\/225Ac-Labeled Agent Targeting PSMA for Highly Efficient\nCancer Radiotheranostics","volume":"66","author":"Tsuchihashi","year":"2023","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026080309073890600_cit29","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1021\/acsmedchemlett.5c00032","article-title":"Development of Novel\nGastrin-Releasing Peptide Receptor-targeted Radioligand with Albumin\nBinder to Improve Accumulation in Tumor","volume":"16","author":"Tsuchihashi","year":"2025","journal-title":"ACS\nMed. Chem. Lett."},{"issue":"8","key":"2026080309073890600_cit30","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1021\/acs.molpharmaceut.2c00201","article-title":"Structure-Activity\nRelationships and Pharmacokinetics of 111In-Labeled Glucagon-like\nPeptide-1 Receptor-Targeting Exendin-4 Derivatives Conjugated with\nAlbumin Binder Moieties","volume":"19","author":"Iikuni","year":"2022","journal-title":"Mol. Pharm."},{"issue":"3","key":"2026080309073890600_cit31","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1021\/acs.molpharmaceut.0c00953","article-title":"Modulation\nof the Pharmacokinetics of a Radioligand Targeting Carbonic Anhydrase-IX\nwith Albumin-Binding Moieties","volume":"18","author":"Iikuni","year":"2021","journal-title":"Mol. Pharm."},{"issue":"1","key":"2026080309073890600_cit32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2967\/jnumed.112.107235","article-title":"DOTA Conjugate with an Albumin-binding Entity Enables\nthe First Folic Acid-targeted 177Lu-radionuclide Tumor\nTherapy in Mice","volume":"54","author":"Mu\u0308ller","year":"2013","journal-title":"J. Nucl. Med."},{"issue":"9","key":"2026080309073890600_cit33","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2967\/jnumed.121.263323","article-title":"Substitution\nof l-Tryptophan by alpha-Methyl-l-Tryptophan in 177Lu-RM2\nResults in 177Lu-AMTG, a High-Affinity Gastrin-Releasing\nPeptide Receptor Ligand with Improved In Vivo Stability","volume":"63","author":"Gu\u0308nther","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026080309073890600_cit34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching Chelators\nto Radiometals for Radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem.\nSoc. Rev."},{"key":"2026080309073890600_cit35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113757","article-title":"Development of Radioligands with\nan Albumin-binding Moiety of 4-(p-Iodophenyl) butyric Acid for Theranostic\nApplications","volume":"382","author":"Meng","year":"2025","journal-title":"J. Controlled Release"},{"key":"2026080309073890600_cit36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejpb.2018.07.011","article-title":"Parenteral\nProtein Formulations: An Overview of Approved Products\nwithin the European Union","volume":"131","author":"Gervasi","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"2026080309073890600_cit37","doi-asserted-by":"publisher","DOI":"10.3390\/children7010001","article-title":"Pediatric Safety of\nPolysorbates in Drug Formulations","volume":"7","author":"Kriegel","year":"2020","journal-title":"Children"},{"issue":"52","key":"2026080309073890600_cit38","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1039\/D1CC00823D","article-title":"Development of a Novel\nRadiotheranostic Platform with a DOTA-based Trifunctional Chelating\nAgent","volume":"57","author":"Nakashima","year":"2021","journal-title":"Chem. Commun."},{"issue":"20","key":"2026080309073890600_cit39","doi-asserted-by":"publisher","first-page":"7890","DOI":"10.1021\/jm400895s","article-title":"Preparation of Asymmetric\nUrea Derivatives That Target Prostate-Specific Membrane Antigen for\nSPECT Imaging","volume":"56","author":"Harada","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026080309073890600_cit40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1021\/acs.molpharmaceut.4c00974","article-title":"Novel Radiotheranostic Ligands Targeting\nProstate-Specific Membrane Antigen Based on Dual Linker Approach","volume":"22","author":"Kazuta","year":"2025","journal-title":"Mol. Pharm."},{"issue":"22","key":"2026080309073890600_cit41","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1016\/j.bmc.2016.09.039","article-title":"Investigation\nof Bombesin Peptide\nas a Targeting Ligand for the Gastrin Releasing Peptide (GRP) Receptor","volume":"24","author":"Begum","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"2026080309073890600_cit42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.apradiso.2014.11.006","article-title":"Evaluation and Comparison of a New DOTA and DTPA-bombesin\nAgonist in vitro and in vivo in Low and High GRPR Expressing Prostate\nand Breast Tumor Models","volume":"96","author":"Pujatti","year":"2015","journal-title":"Appl. Radiat. Isot."},{"issue":"11","key":"2026080309073890600_cit43","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1007\/s00210-023-02539-w","article-title":"PSMA-617 Inhibits\nProliferation and\nPotentiates the 177Lu-PSMA-617-Induced Death of Human Prostate\nCancer Cells","volume":"396","author":"Zhao","year":"2023","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"issue":"9","key":"2026080309073890600_cit44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091371","article-title":"Bispecific GRPR-Antagonistic Anti-PSMA\/GRPR\nHeterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer","volume":"11","author":"Mitran","year":"2019","journal-title":"Cancers"},{"issue":"6","key":"2026080309073890600_cit45","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1021\/acs.molpharmaceut.5c00135","article-title":"Design and Preclinical Evaluation\nof Novel uPAR-Targeting Radiopeptides Modified with an Albumin-Binding\nEntity","volume":"22","author":"Beyer","year":"2025","journal-title":"Mol. Pharm."},{"issue":"24","key":"2026080309073890600_cit46","doi-asserted-by":"publisher","first-page":"9955","DOI":"10.1021\/jm4017448","article-title":"Design, Synthesis,\nand Biological\nActivity of Novel Dicoumarol Glucagon-like Peptide 1 Conjugates","volume":"56","author":"Han","year":"2013","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026080309073890600_cit47","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s11307-020-01500-0","article-title":"The Effects\nof an Albumin Binding Moiety on the Targeting\nand Pharmacokinetics of an Integrin \u03b1v\u03b26-Selective Peptide Labeled with Aluminum [18F]Fluoride","volume":"22","author":"Hausner","year":"2020","journal-title":"Mol. Imaging Biol."},{"issue":"4","key":"2026080309073890600_cit48","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of Prostate-Specific\nMembrane Antigen in Normal and Malignant Human Tissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J. Surg."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00209","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4166\/65921540\/acs.molpharmaceut.6c00209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4166\/65921540\/acs.molpharmaceut.6c00209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:14:13Z","timestamp":1785762853000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/8\/4166\/5208826\/Improving-Pharmacokinetics-of-PSMA-GRPR-Targeting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00209","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00209.s001","asserted-by":"subject"}]},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}